Results 61 to 70 of about 86,485 (257)
Respiratory Research, 2021 Background Data on the safety and efficacy profile of tocilizumab in patients with severe COVID-19 needs to be enriched. Methods In this open label, prospective study, we evaluated clinical outcomes in consecutive patients with COVID-19 and PaO2/FiO2
Theodoros Karampitsakos +15 more
doaj +1 more source
Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. [PDF]
, 2019 OBJECTIVE It is currently unknown how long GCA should be treated with tocilizumab. In the first randomized controlled trial, the biologic agent was stopped after 52 weeks.
Reichenbach, Stephan +5 more
core +1 more source
Distinct Systemic Sclerosis Phenotypes Related to Ethnicity: An Opportunity to Personalize Care?
Arthritis Care &Research, EarlyView.Objective The objective is to describe and compare demographic, clinical, and serological characteristics of patients with systemic sclerosis (SSc) according to ethnic background. Methods Participants enrolled in the Canadian Scleroderma Research Group cohort who self‐identified to a single ethnicity group were included.
Danick Goulet +11 more
wiley +1 more source
Integrated safety in tocilizumab clinical trials [PDF]
Introduction: The efficacy and safety of tocilizumab in patients with rheumatoid arthritis have been evaluated in a comprehensive phase 3 program. Patients from these randomized trials could receive tocilizumab treatment in open-label extension trials ...
Jahreis A +5 more
core +5 more sources
Review of tocilizumab in the treatment of rheumatoid arthritis
Biologics: Targets & Therapy, 2008 Yasuaki OkudaDepartment of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama-city, Ehime, JapanAbstract: Constitutively overproduced in proliferating synovial tissues, interleukin-6 (IL-6) is deeply involved in the pathology
Yasuaki Okuda
doaj
Antibiotics, 2023 We aimed to assess the factors associated with mortality in patients treated with tocilizumab for a SARS-CoV-2 pneumonia due to the delta or omicron variants of concern (VOC) and detect an effect of tocilizumab on mortality.
Paul Laffont-Lozes +14 more
doaj +1 more source
Arthritis Care &Research, EarlyView.Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato +27 more
wiley +1 more source
, 2014 Tocilizumab combined with methotrexate versus single DMARD (methotrexate): The effect of tocilizumab is significant (Z = 4.70).
Thorbjørn Hubeck-Graudal (632411) +4 more
core +1 more source
Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis. [PDF]
, 2018 Objective Tocilizumab is effective in inducing and maintaining remission of GCA. Despite clinical and serological control of disease, magnetic resonance angiography may show persistence of inflammatory signals of unknown significance in arterial walls.
Stefan Kuchen +13 more
core +3 more sources
Arthritis Care &Research, EarlyView.Objective Elevated C‐reactive protein (CRP) levels in systemic sclerosis (SSc) have been linked with severe disease and worse survival, but the role of platelet levels remains unclear. This study examined whether elevated platelet levels, CRP levels, or both are associated with disease severity, progression, and survival in SSc.
Brian S. Lee +4 more
wiley +1 more source